Details for New Drug Application (NDA): 016775
✉ Email this page to a colleague
NDA 016775 describes SERENTIL, which is a drug marketed by Novartis and is included in three NDAs. Additional details are available on the SERENTIL profile page.
The generic ingredient in SERENTIL is mesoridazine besylate. There are two drug master file entries for this compound. Additional details are available on the mesoridazine besylate profile page.
The generic ingredient in SERENTIL is mesoridazine besylate. There are two drug master file entries for this compound. Additional details are available on the mesoridazine besylate profile page.
Summary for 016775
| Tradename: | SERENTIL |
| Applicant: | Novartis |
| Ingredient: | mesoridazine besylate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 016775
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 25MG BASE/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
